Calprotectin belongs to the group of Ca-binding proteins of the S100 family and is present in large amounts in neutrophilic granulocytes, where it accounts for 5% of total proteins and 60% of the proteins of the cytoplasmatic portion. The increase of faecal Calprotectin appears to be due to faecal excretion of neutrophils and macrophages migrated from the blood stream into the intestinal lumen through the inflamed mucosa. A strict correlation has been demonstrated between the Calprotectin levels and the clinical indexes of disease activity in patients with IBD.
In association with clinical findings, Calprest® NG can be used for the in vitro diagnosis, follow-up and treatment monitoring of patients affected by Inflammatory Bowel Disease (IBD), Irritable Bowel Syndrome as well as for screening and surveillance of high-risk CRC patients.
Crohn’s disease (CD) and ulcerous colitis (UC) are chronic inflammatory bowel diseases (IBD) with unknown aetiology. Their prevalence is extremely variable in the different case studies: about 40/100.000 for CD and 100/100.000 for UC. The annual incidence rate is about 4/100,000 inhabitants for CD and 8/100,000 for UC. Colorectal cancer (CRC), whose known main risk factors are genetic predisposition, diet, presence of IBD and age, has an yearly rate incidence of 25/100.000 in Western Europe and USA populations.